Clinical trial · Interventional
Impact of Intravenous Lidocaine During Colorectal Surgery on Pain and Immune Functions
Impact of Intraoperative Intravenous Lidocaine Administered During Laparoscopic Colorectal Surgery on Remifentanil Consumption, Postoperative Pain and Immune Cell Activity: A Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates the impact of intraoperative intravenous lidocaine administered during laparoscopic colorectal surgery on the intraoperative remifentanil consumption as well as postoperative pain and opioid requirements. It will evaluate immune cell activity for 48hours after surgical stress and general anesthesia with or without intravenous lidocaine.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Intravenous Lidocaine and Immunity | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| intravenous lidocaine (IVL) | Drug | — | UNRESOLVED |
| Placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- intravenous lidocaine (IVL)
- description
- Will receive during the colorectal surgery under General Anesthesia intravenous lidocaine bolus 1.5mg/kg at the beginning of anesthesia (induction) and 1.5mg/kg/h until the end of anesthesia.
- interventionNames
- Drug: intravenous lidocaine (IVL)
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Will receive the same volume of normal saline for the entire duration of anesthesia.
- interventionNames
- Other: Placebo
Primary outcomes (1)
- measure
- Reduction of total intraoperative remifentanil consumption by 30% in the intravenous lidocaine ("IVL") group compared with the control group ("C"). Total consumption of remifentanil in mcg.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ASA status I, II or III * Patients older than 18 years * Colonic surgery * Classical management of ERAS program patients in our center Exclusion Criteria: * Arrhythmia, abnormal electrocardiographic , antiarrhythmic therapy * Immunosuppressive treatments, corticosteroids or long-term NSAIDs (multiple weekly doses) or during preoperative 48 hours * conversion intraoperative of a laparoscopic surgical technique to a laparotomy technique * Pregnant women * Inability to complete the questions related to this study * Inability to use hydromorphone postoperative PCA * Intolerance or allergy to lidocaine, hydromorphone or any other drug that is included in the protocol for perioperative management Unexpected events leading to the exclusion: * Difficult unplanned intubation * Surgical complication requiring aggressive haemodynamic support (vasopressors, inotropes, transfusion)
References
Publications (0)
Data not yet available